$ZBH

Zimmer Biomet Holdings (ZBH) announced a third-quarter 2026 cash dividend of $0.24 per share. The company's stock is trading at $100.04, with recent gains of 19.45% over 90 days and 6.50% over 30 days, but longer-term returns are down 4.72% over one year and 26.62% over five years. Analysts suggest the stock is 7% undervalued, with a fair value estimate of $107.57, citing growth in digital health and robotics. However, the company faces pricing pressures and integration challenges from recent ac

Zimmer Biomet (ZBH) reported Q2 results on Aug. 5, with adjusted EPS of $2.07 vs $2.01 expected and revenue of $2.2B vs $2.1B forecast. The company guided full-year adjusted EPS to $8.47-$8.59. Analysts covering ZBH have a Hold consensus, with a mean price target of $104.67 and a Street-high of $125.

Zimmer Biomet reported Q2 2026 organic constant-currency revenue growth of 4%, led by a 4.6% U.S. increase and 3.1% international growth. Management raised full-year organic guidance to 2.25%-3.25% and adjusted EPS to $8.47-$8.59, including $1B planned 2026 share repurchases. China revenue fell 20%.

Bernstein raised its price target on Zimmer Biomet to $93 from $91, according to the report. The article also notes a separate Jefferies price target change to $105 from $95. Investors may use these analyst updates as inputs for valuation and expectations for the stock.

Zimmer Biomet reported Q2 revenue of about $2.18bn, up 4.8% YoY. Knees led at $828.9m, followed by S.E.T. at $586m and hips at $562.7m. The company raised its 2026 revenue growth outlook to 3.9% to 4.9% and adjusted EPS to $8.47 to $8.59 per diluted share. Shares rose over 5% to about $101 at the open.

Zimmer Biomet (ZBH) reported Q2 2026 adjusted EPS of $2.07, above the $2.01 consensus, and net sales of $2.18B, above the $2.13B estimate. GAAP EPS was $1.03. The company raised 2026 guidance, including revenue growth to 3.9% to 4.9% and adjusted EPS to $8.47 to $8.59. Shares rose 1.4% pre-market.

Zimmer Biomet (ZBH) reported Q2 sales up 4.8% reported and 4% organically, citing strength in the U.S. and technology segments. The company said product momentum and the Paragon 28 integration supported results and raised 2026 guidance for both revenue and adjusted EPS, according to its Q2 2026 transcript.

Zimmer Biomet (NYSE:ZBH) reported Q2 CY2026 revenue of $2.18 billion, up 4.8% year on year and 2% above analysts’ estimates, according to the company. Non-GAAP adjusted EPS was $2.07, about 3% above consensus. The article also cites full-year EPS expectations rising from $8.48 to $8.72 and notes the stock rose about 3% to $98.68 after results.

Zimmer Biomet (ZBH) shares rose about 4.5% in pre-open after the company reported Q2 2026 results. Analysts expected EPS of $2.01 and revenue of about $2.13–$2.14B; the company beat estimates. UBS upgraded ZBH to Buy from Sell on July 28, setting a $115 target. Peer results from CONMED and Baxter also beat.

ZIMMER BIOMET HOLDINGS, INC. (ZBH) filed an SEC Form 8-K — Results of Operations and Financial Condition. 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Troy Kirkpatrick David DeMartino 614-284-1926 646-531-6115 troy.kirkpatrick@zimmerbiomet.com david.demartino@zimmerbiomet.com Kirsten Fallon Zach Weiner 781-779-5561 908-591-6955 kirsten.fallon@zim